In vitro and in vivo safety studies indicate that R15, a synthetic polyarginine peptide, could safely reverse the effects of unfractionated heparin.

导出 OA

翻译打印收藏纠错

第一作者： Tong,Li

第一单位： Department of Pharmaceutical Sciences, Beijing Institute of Radiation Medicine, China.

作者： Tong,Li ^[1] ; Zhiyun,Meng ^[1] ; Xiaoxia,Zhu ^[1] ; Hui,Gan ^[1] ; Ruolan,Gu ^[1] ; Zhuona,Wu ^[1] ; Taoyun,Liu ^[1] ; Peng,Han ^[1] ; Jiarui,Gao ^[1] ; Su,Han ^[1] ; Guifang,Dou ^[1]

作者单位： Department of Pharmaceutical Sciences, Beijing Institute of Radiation Medicine, China. ^[1]

关键词 heparin reversal heparin substitutes immunogenicity polyarginine protamine

主题词动物(Animals);血液凝固(Blood Coagulation);血液凝固试验(Blood Coagulation Tests);补体激活(Complement Activation);药物拮抗作用(Drug Antagonism);红细胞(Erythrocytes);纤维蛋白(Fibrin);肝素(Heparin);肝素拮抗药(Heparin Antagonists);人类(Humans);肽类(Peptides);鱼精蛋白类(Protamines);大鼠(Rats)

DOI 10.1002/2211-5463.13240

PMID 34184429

发布时间 2022-03-28

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

FEBS open bio

2021年11卷9期

2468-2489页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

In vitro and in vivo safety studies indicate that R15, a synthetic polyarginine peptide, could safely reverse the effects of unfractionated heparin.

FEBS open bio

相似文献

FEBS open bio

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

In vitro and in vivo safety studies indicate that R15, a synthetic polyarginine peptide, could safely reverse the effects of unfractionated heparin.

FEBS open bio

相似文献

FEBS open bio

相关期刊

检索历史清除